NASDAQ:VERU - Veru Stock Price, Forecast & News

Veru trades on the NASDAQ under the ticker symbol "VERU."

Veru Inc (NASDAQ:VERU) released its earnings results on Wednesday, February, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The firm earned $10.58 million during the quarter, compared to the consensus estimate of $9.30 million. Veru had a negative return on equity of 40.45% and a negative net margin of 36.58%. View Veru's Earnings History.

Veru is scheduled to release their next quarterly earnings announcement on Wednesday, May 20th 2020. View Earnings Estimates for Veru.

5 Wall Street analysts have issued twelve-month price targets for Veru's stock. Their forecasts range from $5.00 to $12.00. On average, they anticipate Veru's stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price. View Analyst Price Targets for Veru.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.

Press coverage about VERU stock has trended somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Veru earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the next several days. View News Stories for Veru.

Veru saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 238,900 shares, an increase of 109.0% from the January 15th total of 114,300 shares. Based on an average daily volume of 306,600 shares, the short-interest ratio is presently 0.8 days. Currently, 0.5% of the company's shares are sold short. View Veru's Current Options Chain.

Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Medifast (MED), Revlon (REV) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Opko Health (OPK), Genocea Biosciences (GNCA), NovaBay Pharmaceuticals (NBY), Strongbridge Biopharma (SBBP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE) and Novavax (NVAX).

Veru's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.39%), Geode Capital Management LLC (0.56%), EAM Investors LLC (0.46%), Wedge Capital Management L L P NC (0.45%), Credit Suisse AG (0.17%) and Raymond James & Associates (0.14%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Institutional Ownership Trends for Veru.

VERU stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates and UBS Group AG. View Insider Buying and Selling for Veru.

VERU stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, EAM Investors LLC, Credit Suisse AG, Wedge Capital Management L L P NC, Geode Capital Management LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC and Alpine Global Management LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Insider Buying and Selling for Veru.

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VERU stock can currently be purchased for approximately $4.54.

Veru has a market capitalization of $295.98 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe.View Additional Information About Veru.

The official website for Veru is http://www.veruhealthcare.com/.

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]